Synthetic Biologics, Inc.(NYSE Amex Equities : SYN)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 0.95% | 171.30 | 1.3% | $495.18m | |
| BIIB | Biogen Inc. | 0.91% | 235.04 | 1.3% | $480.36m | |
| CELG | Celgene Corporation | 0.11% | 96.36 | 1.3% | $457.23m | |
| GILD | Gilead Sciences, Inc. | -0.03% | 66.50 | 0.9% | $434.72m | |
| ILMN | Illumina, Inc. | 2.08% | 312.83 | 3.5% | $317.70m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.27% | 320.09 | 2.6% | $298.61m | |
| A | Agilent Technologies, Inc. | -0.50% | 67.98 | 1.6% | $207.68m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 1.92% | 172.37 | 1.9% | $181.17m | |
| EXAS | Exact Sciences Corporation | -2.10% | 94.91 | 25.3% | $163.66m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.97% | 127.55 | 2.0% | $149.64m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.25% | 87.69 | 4.3% | $118.55m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.36% | 121.62 | 14.7% | $112.14m | |
| INCY | Incyte Corporation | 0.43% | 79.02 | 2.5% | $105.72m | |
| IONS | Ionis Pharmaceuticals, Inc. | -0.98% | 68.56 | 8.2% | $98.74m | |
| ALNY | Alnylam Pharmaceuticals, Inc | -0.09% | 67.81 | 9.2% | $94.94m |
Company Profile
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.